**Acurx Pharmaceuticals Receives Positive EMA Opinion for Pediatric Study of Ibezapolstat** Acurx Pharmaceuticals Inc. $(ACXP)$ announced it has received a positive opinion from the Paediatric Committee $(PDCO)$ of the European Medicines Agency $(EMA)$ regarding its Pediatric Investigation Plan $(PIP)$ for ibezapolstat, a novel antibiotic for treating Clostridioides difficile infection (CDI) in children. This regulatory milestone fulfills a key EMA requirement ahead of the planned Phase 3 clinical trials in Europe. The company, which has also been granted FDA Qualified Infectious Disease Product (QIDP) and Fast-Track Designation, will now proceed with a similar PIP submission to the U.S. FDA. No grant or funding from multiple organizations was announced-this update pertains solely to Acurx's regulatory progress. If successful, ibezapolstat could receive an additional year of marketing exclusivity in Europe on top of the standard 10-year exclusivity for new antibiotics.